Aperio Group LLC Boosts Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Aperio Group LLC increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 23,371 shares of the medical research company’s stock after buying an additional 594 shares during the period. Aperio Group LLC’s holdings in Charles River Laboratories International were worth $5,292,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Copper Rock Capital Partners LLC increased its stake in shares of Charles River Laboratories International by 4,082.5% in the second quarter. Copper Rock Capital Partners LLC now owns 4,303,347 shares of the medical research company’s stock worth $679,474,000 after purchasing an additional 4,200,458 shares in the last quarter. FMR LLC increased its stake in shares of Charles River Laboratories International by 18.2% in the second quarter. FMR LLC now owns 1,945,690 shares of the medical research company’s stock worth $339,231,000 after purchasing an additional 299,655 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC increased its stake in shares of Charles River Laboratories International by 22.4% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 792,643 shares of the medical research company’s stock worth $138,197,000 after purchasing an additional 145,047 shares in the last quarter. King Luther Capital Management Corp increased its stake in shares of Charles River Laboratories International by 2.6% in the second quarter. King Luther Capital Management Corp now owns 408,559 shares of the medical research company’s stock worth $71,232,000 after purchasing an additional 10,501 shares in the last quarter. Finally, Bellevue Group AG increased its stake in shares of Charles River Laboratories International by 10.3% in the second quarter. Bellevue Group AG now owns 365,833 shares of the medical research company’s stock worth $63,783,000 after purchasing an additional 34,210 shares in the last quarter. Hedge funds and other institutional investors own 87.83% of the company’s stock.

Shares of CRL opened at $232.54 on Friday. The firm has a market cap of $11.57 billion, a price-to-earnings ratio of 38.76, a PEG ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.22 and a current ratio of 1.45. Charles River Laboratories International, Inc. has a fifty-two week low of $95.58 and a fifty-two week high of $257.88. The firm has a 50 day moving average price of $236.51 and a 200-day moving average price of $204.07.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, October 29th. The medical research company reported $2.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.53. Charles River Laboratories International had a net margin of 10.68% and a return on equity of 22.41%. The firm had revenue of $743.30 million during the quarter, compared to analyst estimates of $715.63 million. During the same period in the previous year, the business posted $1.69 EPS. The business’s quarterly revenue was up 11.3% on a year-over-year basis. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 7.86 earnings per share for the current year.

CRL has been the subject of a number of analyst reports. Truist raised their price objective on shares of Charles River Laboratories International from $237.00 to $256.00 in a research report on Tuesday, November 3rd. KeyCorp raised their price objective on shares of Charles River Laboratories International from $186.00 to $233.00 and gave the company an “overweight” rating in a research report on Tuesday, August 18th. Citigroup raised their price objective on shares of Charles River Laboratories International from $190.00 to $255.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and raised their price objective for the company from $213.00 to $254.00 in a research report on Thursday, September 10th. Finally, Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $261.00 price objective for the company in a research report on Tuesday, November 3rd. Two investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $210.58.

In related news, Director George Massaro sold 1,943 shares of Charles River Laboratories International stock in a transaction on Monday, September 14th. The shares were sold at an average price of $219.91, for a total value of $427,285.13. Following the transaction, the director now directly owns 11,384 shares of the company’s stock, valued at $2,503,455.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard F. Wallman bought 1,150 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was purchased at an average cost of $232.96 per share, for a total transaction of $267,904.00. Following the completion of the purchase, the director now owns 31,715 shares of the company’s stock, valued at $7,388,326.40. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 32,832 shares of company stock worth $7,734,306. 1.90% of the stock is owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: What is Compound Annual Growth Rate (CAGR)?

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.